课题基金 / 基金详情

UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program

UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
北卡罗来纳大学-杜克大学合作临床药理学博士后培训项目
批准号:
10645033
负责人:
KIM L.R. BROUWER
金额:
$74.43万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
未结题
起止时间:
2011-07-01 至 2026-06-30

项目摘要

项目成果

KIM L.R. BROUWER的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 位于查佩尔山的北卡罗来纳州大学与杜克大学合作, T32临床药理学博士后培训计划,建立在我们卓越的研究基础上 在药物发现、药物开发、药代动力学/ 药效学、儿科临床药理学和药物安全性。对临床药理学家的需求 我们在培训临床科学家以满足不断增长的劳动力方面有着出色的记录 这个领域的需要。我们有一个优秀的和多样化的申请人池与更多的合格申请人比 资金到位。此更新申请(11-15年级)描述了我们的2年培训计划(4个新的 学员/年),提供强大的领导力,来自多个学科的国际公认的导师, 积极参与临床药理学,广泛的尖端技术和资源,以及 独特的合作环境,强大的机构支持。国家申请人池 该计划主要来自医学专业培训计划中的医学博士,他们寻求临床职业道路 药理学,也从药学博士在先进的临床/转化研究培训。受训人员, 个性化的发展计划和指导团队,完成临床药理学课程, 从事特定项目的活动,以获得当代临床药理学各方面的专业知识 研究,为成功的学术,监管或工业职业生涯做准备,作为领导者和导师, 未来几代临床药理学家。经验丰富的教师导师是根据他们的选择, 研究生产力在至少四个重点领域之一,形成这个培训计划的核心:药物 处置和行动;定量药理学/药物计量学和临床试验设计;个体化 治疗;药物诱导的器官毒性。该培训计划的新内容包括更加注重 精确给药,使用真实世界的数据和药物计量学;扩大临床试验计划 专业和创新领域的药理学培训;增强专业发展机会; 并与其他T32项目扩大合作。这项培训计划的一个独特之处是, 我们的重点是临床药理学的未充分研究领域,特别是儿科和药物安全。的 我们的实习生对临床药理学有浓厚的兴趣, 药理学研究资源在杜克大学和杜克,智力丰富的生物医学科学环境, 三角研究园,以及我们长期以来优秀的研究和培训基础设施联合收割机, 这是临床药理学培训的绝佳机会
英文摘要
ABSTRACT The University of North Carolina at Chapel Hill (UNC) in collaboration with Duke University has a successful T32 postdoctoral training program in clinical pharmacology that builds on our exceptional research environment with world-class programs in drug discovery, drug development, pharmacokinetics/ pharmacodynamics, pediatric clinical pharmacology, and drug safety. The demand for clinical pharmacologists is high, and we have an outstanding track record of training clinician-scientists to meet the growing workforce needs in this field. We have an excellent and diverse applicant pool with many more qualified applicants than funded positions. This renewal application (Years 11-15) describes our 2-year training program (4 new trainees/year), which offers strong leadership, internationally-recognized mentors from multiple disciplines who are actively involved in clinical pharmacology, a wide-array of cutting edge technologies and resources, and a uniquely collaborative environment with strong institutional support. The national applicant pool for this program is derived primarily from MDs in medical specialty training programs seeking a career path in clinical pharmacology, and also from PharmDs in advanced clinical/translational research training. Trainees, guided by individualized development plans and mentoring teams, complete clinical pharmacology coursework and engage in program-specific activities to gain expertise in all aspects of contemporary clinical pharmacology research in preparation for successful academic, regulatory or industrial careers as leaders and mentors to future generations of clinical pharmacologists. Experienced faculty mentors are chosen based on their research productivity in at least one of four focus areas that form the core of this training program: Drug Disposition and Action; Quantitative Pharmacology/Pharmacometrics & Clinical Trial Design; Individualized Therapy; Drug-induced Organ Toxicity. New components of this training program include an increased focus on precision dosing, use of real-world data, and pharmacometrics; pilot programs to expand clinical pharmacology training in specialty and innovative areas; enhanced professional development opportunities; and expansion of collaborations with other T32 programs. A unique feature of this training program continues to be our focus on understudied areas in clinical pharmacology, specifically pediatrics and drug safety. The keen interest in clinical pharmacology within our trainee pool, the unparalleled investment in clinical pharmacology research resources at UNC and Duke, the intellectually-rich biomedical science environment of Research Triangle Park, and our longstanding excellent research and training infrastructure combine to create a moment of unsurpassed opportunity for training in clinical pharmacology.
期刊论文(86)
专著(0)
科研奖励(0)
会议论文
Injectable pH and Thermo-Responsive Hydrogel Scaffold with Enhanced Osteogenic Differentiation of Preosteoblasts for Bone Regeneration.
可注射的pH和热响应水凝胶支架,具有增强的骨骼再生前成骨细胞成骨分化。
DOI: 10.3390/pharmaceutics15092270
发表时间: 2023-09-02
期刊: Pharmaceutics
影响因子: 5.4
作者: [King JL, Shrivastava R, Shah PD, Maturavongsadit P, Benhabbour SR]
通讯作者: Benhabbour SR
β blockers for heart failure: which works best?
β受体阻滞剂治疗心力衰竭:哪种效果最好?
DOI: 10.1136/bmj.f480
发表时间: 2013
期刊: BMJ (Clinical research ed.)
影响因子: --
作者: [Mentz,RobertJ]
通讯作者: Mentz,RobertJ
DOI: 10.1002/ijc.34215
发表时间: 2022
期刊: International journal of cancer
影响因子: 6.4
作者: [Commander,SarahJane, Cerullo,Marcelo, Arjunji,Neha, Leraas,HaroldJ, Thornton,Steven, Ravindra,Kadiyala, Tracy,ElisabethT]
通讯作者: Tracy,ElisabethT
DOI: 10.1002/jcph.1739
发表时间: 2021-03
期刊: Journal of clinical pharmacology
影响因子: 2.9
作者: [Commander SJ, Wu H, Boakye-Agyeman F, Melloni C, Hornik CD, Zimmerman K, Al-Uzri A, Mendley SR, Harper B, Cohen-Wolkowiez M, Hornik CP, Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee]
通讯作者: Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee
40
    Duke-UNC Collaborative Pediatric Clinical Pharmacology Postdoctoral Training Program
    • 批准号:
      10400677
    • 项目类别:
    • 资助金额:
      $19.2万
    • 财政年份:
      2021
    • 负责人:
      KIM L.R. BROUWER
    • 依托单位:
    Duke-UNC Collaborative Pediatric Clinical Pharmacology Postdoctoral Training Program
    • 批准号:
      10626740
    • 项目类别:
    • 资助金额:
      $18.51万
    • 财政年份:
      2021
    • 负责人:
      KIM L.R. BROUWER
    • 依托单位:
    Duke-UNC Collaborative Pediatric Clinical Pharmacology Postdoctoral Training Program
    • 批准号:
      10173438
    • 项目类别:
    • 资助金额:
      $18.4万
    • 财政年份:
      2021
    • 负责人:
      KIM L.R. BROUWER
    • 依托单位:
    Mechanisms of Altered Hepatic Transport: Impact on Drug Therapy
    海外基金